BAF312
ApprovedSmall molecule
NovartisBAF312 is one of 141 small molecule programs targeting Polymyositis. It is currently in Approved.
5
Indications
10
Total Trials
0
Active Trials
140
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
107 competitors in Relapsing-Remitting Multiple Sclerosis
#DrugCompanyPhaseTrials
1Copaxone
TevaPhase 3
Betaseron
BayerPhase 3
Aubagio
SanofiPhase 3
BAF312
NovartisApproved
Avonex
EMD SeronoPhase 3
Fluzone
SanofiPhase 3
Rituxan
RochePhase 3
Robitussin
PfizerPhase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dermatomyositis2 trials
Relapsing-Remitting Multiple Sclerosis2 trials
Secondary Progressive Multiple Sclerosis2 trials
Renal Impairment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BAF312. EMBL-EBI & Wellcome Sanger Institute.
- [4]